Trial Profile

A clinical study of Maraciclatide for Visualization of Inflammation in Interstitial Lung Disease.

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Maraciclatide (Primary)
Indications Inflammation
Focus Diagnostic use
Acronyms PREDICT-ILD

Most Recent Events

20 Feb 2026 New trial record
12 Feb 2026 According to SERAC Healthcare media release, Phase II preliminary data from the PRospective Evaluation of Interstitial Lung Disease progression with quantitative CT (PREDICT-ILD)' trial have demonstrated that visualisation of inflammation in people with fibrotic-ILD could be feasible with 99mTc-maraciclatide. Further clinical results will be published later this year.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com